NZ571118A - Combination treatment of metabolic disorders - Google Patents

Combination treatment of metabolic disorders

Info

Publication number
NZ571118A
NZ571118A NZ571118A NZ57111807A NZ571118A NZ 571118 A NZ571118 A NZ 571118A NZ 571118 A NZ571118 A NZ 571118A NZ 57111807 A NZ57111807 A NZ 57111807A NZ 571118 A NZ571118 A NZ 571118A
Authority
NZ
New Zealand
Prior art keywords
compound
methyl
rosiglitazone
diabetes
hydrogen
Prior art date
Application number
NZ571118A
Other languages
English (en)
Inventor
Borstel Reid W Von
Kirvin L Hodge
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of NZ571118A publication Critical patent/NZ571118A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ571118A 2006-03-31 2007-03-05 Combination treatment of metabolic disorders NZ571118A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74402106P 2006-03-31 2006-03-31
PCT/US2007/063288 WO2007117791A2 (en) 2006-03-31 2007-03-05 Combination treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
NZ571118A true NZ571118A (en) 2011-12-22

Family

ID=38581719

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ571118A NZ571118A (en) 2006-03-31 2007-03-05 Combination treatment of metabolic disorders

Country Status (11)

Country Link
US (1) US8338480B2 (enExample)
EP (1) EP2001461A4 (enExample)
JP (1) JP2009532372A (enExample)
KR (1) KR20080106455A (enExample)
CN (1) CN101410105A (enExample)
AU (1) AU2007235145B2 (enExample)
CA (1) CA2647258A1 (enExample)
IL (1) IL194189A0 (enExample)
MX (1) MX2008012506A (enExample)
NZ (1) NZ571118A (enExample)
WO (1) WO2007117791A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009525982A (ja) * 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
MX2010002562A (es) * 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8829058B2 (en) * 2008-03-13 2014-09-09 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
US9805725B2 (en) 2012-12-21 2017-10-31 Dolby Laboratories Licensing Corporation Object clustering for rendering object-based audio content based on perceptual criteria
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
JP6660668B2 (ja) * 2014-06-24 2020-03-11 花王株式会社 Ｕｃｐ−１発現促進剤
US10758519B2 (en) 2014-06-24 2020-09-01 Kao Corporation UCP-1 expression promoter
WO2015199097A1 (ja) * 2014-06-24 2015-12-30 花王株式会社 Ｕｃｐ－１発現促進剤
JP6553375B2 (ja) * 2014-06-24 2019-07-31 花王株式会社 Ｕｃｐ−１発現促進剤
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CN1543451A (zh) * 2001-06-07 2004-11-03 过氧化物酶体增生剂激活的受体的调节剂
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
CA2502297C (en) * 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
ES2353601T3 (es) * 2003-04-15 2011-03-03 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos.
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA06001963A (es) * 2003-08-20 2006-05-31 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2887881B1 (fr) 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
US7820721B2 (en) * 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
KR20080106455A (ko) 2008-12-05
IL194189A0 (en) 2009-08-03
CA2647258A1 (en) 2007-10-18
WO2007117791A2 (en) 2007-10-18
CN101410105A (zh) 2009-04-15
US8338480B2 (en) 2012-12-25
JP2009532372A (ja) 2009-09-10
AU2007235145B2 (en) 2011-09-22
US20100292277A1 (en) 2010-11-18
AU2007235145A1 (en) 2007-10-18
WO2007117791A3 (en) 2008-08-21
EP2001461A4 (en) 2010-06-09
EP2001461A2 (en) 2008-12-17
MX2008012506A (es) 2008-10-14

Similar Documents

Publication Publication Date Title
AU2007235145B2 (en) Combination treatment of metabolic disorders
US7645772B2 (en) Treatment of metabolic disorders
JP2019524808A (ja) アモジアキンおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
EP2037736A1 (en) Methods for treating cystic kidney diseases
JP2000514807A (ja) レプチン耐性の新規な治療
AU2003299772C1 (en) Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity
AU2001277926B2 (en) Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
KR100798217B1 (ko) 당뇨병을 치료하기 위한 피탄산의 용도
Edgley et al. PPARγ agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats
AU2001277926A1 (en) Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
MX2008015640A (es) Compuestos para el tratamiento de trastornos metabolicos.
KR102524408B1 (ko) 아모디아퀸 및 아르테수네이트계 약물을 유효성분으로 함유하는 제2형 당뇨병 예방 또는 치료용 약학적 조성물
AU2003260380B2 (en) Use of a PPAR-alpha agonist to treat weight gain associated with a PPAR-gamma agonist treatment

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed